蛋白质组分析显示,Acalypha australis L.通过调节FABP4/PPARγ/NF-κB信号通路来缓解慢性结肠炎
Xiaoyu Quan1, Zhiwei Miao2, Runxi Han3
1College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.
Journal of ethnopharmacology
|March 6, 2025
概括
澳洲 (Acalypha australis L.) (AAL) 通过改善肠道屏障功能和通过FABP4/PPARγ/NF-κB通路减少炎症,有效治疗慢性结肠炎. 柏加普托和科里拉金等关键化合物显示出治疗性结肠炎的治疗潜力.
科学领域:
- 药理学和天然产品研究 药理学和天然产品研究
- 胃肠病学和炎症性肠病研究
- 分子生物学和信号通路分析
背景情况:
- 阿卡利法 (Acalypha australis) L. (AAL) 是一种具有抗炎功能的传统中国草药,传统上用于胃肠道问题.
- 之前的研究表明AAL在急性结肠炎中的有效性,但其在慢性结肠炎中的作用和潜在机制尚不清楚.
- 了解AAL在慢性结肠炎中的治疗潜力对于开发新型自然疗法至关重要.
研究的目的:
- 为了评估AAL在硫酸 (DSS) 诱导的慢性结肠炎小鼠模型中的治疗疗效.
- 阐明AAL的抗炎和屏障保护机制,重点关注FABP4/PPARγ/NF-κB信号通路.
- 为了确定AAL中潜在的生物活性化合物,负责其治疗效果.
主要方法:
- 使用UPLC-QTOF-MS对AAL进行化学分析;通过重复的DSS给药在小鼠中诱导慢性结肠炎.
- 通过临床评分 (DAI),体重,结肠长度和组织病理学来评估治疗效果.
- 通过免疫组织化学和西式涂抹对炎性细胞因子 (ELISA),粘膜屏障蛋白 (MUC2,ZO-1,Occludin) 和信号蛋白 (FABP4,PPARγ,p-P65) 的分析;还采用了蛋白质组分析,分子对接和分子动力学模拟.
主要成果:
- 通过对MUC2,ZO-1和奥克卢丁进行上调,AAL治疗显著改善了慢性结肠炎症状,并保持了肠粘膜完整性.
- 蛋白质和分子分析显示,AAL通过抑制FABP4,增强PPARγ和抑制NF-κB激活来调节FABP4/PPARγ/NF-κB通路.
- 伯加普托和科里拉金被确定为主要的生物活性化合物,与FABP4和PPARγ具有强烈的结合亲和关系,验证了它们在AAL治疗效果中的作用.
结论:
- 在慢性结肠炎中,Acalypha australis L.通过增强肠道屏障功能和减少炎症,显示出显著的治疗疗效.
- 该机制涉及FABP4/PPARγ/NF-κB信号通路的调节,其中伯加普托和科里拉丁被确定为关键活性成分.
- AAL代表了一种有前途的天然治疗剂,用于治疗性结肠炎.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
291
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
291


